Asosiy kontentga oʻtish
Boshqa

EVALUATION OF THE EFFICACY OF THE ANGIOTENSIN RECEPTOR–NEPRILYSIN INHIBITOR (SACUBITRIL/VALSARTAN) IN PATIENTS WITH CHRONIC HEART FAILURE AND RENAL DYSFUNCTION.

Iqboljon Mullaboyev TolibovTashkent State Medical UniversityDurdona Shuhratovna AdilovaTashkent State Medical University
ABI

Annotatsiya

Chronic heart failure (CHF) is frequently accompanied by renal dysfunction, forming cardiorenal syndrome and significantly worsening prognosis. Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), has demonstrated superior outcomes compared with conventional renin–angiotensin system blockade; however, data in patients with impaired renal function remain limited. To evaluate the clinical efficacy, cardiac remodeling effects, and renal safety of sacubitril/valsartan in patients with chronic heart failure and renal dysfunction.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

0 ta iqtibos0 ta foydalanilgan manba